| Company Name: |
cjbscvictory |
| Tel: |
13348960310 13348960310 |
| Email: |
3003867561@qq.com |
Sch412348 manufacturers
- Sch412348
-
- $1980.00
-
2026-05-11
- CAS:377727-26-9
- Purity:
- Supply Ability: 10g
- Sch412348
-
- $1980.00
-
2025-07-21
- CAS:377727-26-9
- Purity:
- Supply Ability: 10g
|
| | Sch412348 Basic information |
| Product Name: | Sch412348 | | Synonyms: | Sch412348;7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 7-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-;Sch412348,Sch-412348 | | CAS: | 377727-26-9 | | MF: | C22H21F2N9O | | MW: | 465.46 | | EINECS: | | | Product Categories: | | | Mol File: | 377727-26-9.mol |  |
| | Sch412348 Chemical Properties |
| density | 1.62±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 5.88±0.10(Predicted) |
| | Sch412348 Usage And Synthesis |
| Uses | Sch412348 is a potent competitive antagonist of the human adenosine A2A receptor (Ki=0.6 nM) and has >1000-fold selectivity over all other adenosine receptors. | | in vivo | Oral administration of Sch412348 (0.1-1 mg/kg) to rats potentiates 3,4-dihydroxy-L-phenylalanine (L-Dopa)-induced contralateral rotations after 6-hydroxydopamine lesions in the medial forebrain bundle and potently attenuates the cataleptic effects of haloperidol. Sch412348 (1 and 3 mg/kg) dose-dependently attenuates haloperidol-induced catalepsy 1 h [F(3,20)=3.9, p<0.05] and 4 h [F(3,20)=7.5, p<0.01] after dosing. Sch412348 [F(2,51) =10.6, p<0.01] (0.1-1 mg/kg) reduces immobility time in the mouse tail suspension test (TST) at 1 mg/kg. Sch412348 (SCH 412348) significantly increases activity levels in the mouse [F(4,27)=2.9, p<0.05]. Both the 0.3 and 3 mg/kg treatment groups are significantly more active than vehicle-treated mice. The 1 mg/kg group approached significance (p=0.052)[1]. | | References | [1] Hodgson RA, et al. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther. 2009 Jul;330(1):294-303. DOI:10.1124/jpet.108.149617 |
| | Sch412348 Preparation Products And Raw materials |
|